Profile
NCNA VRTX REGN VRNA ARGX ALNY
Company Name NuCana plc Vertex Pharmaceuticals Incorporated Regeneron Pharmaceuticals, Inc. Verona Pharma plc argenx SE Alnylam Pharmaceuticals, Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology
Market Cap $12.69M $122.53B $76.58B $72.68B $50.22B $43.35B
Employees 0.02K 6.10K 15.16K 0.21K 1.60K 2.23K
CEO Hugh Stephen Griffith Reshma Kewalramani Leonard S. Schleifer David S. Zaccardelli Timothy Van Hauwermeiren Yvonne L. Greenstreet
Ratings
NCNA VRTX REGN VRNA ARGX ALNY
Quant Rating Score 3 4 4 1 4 3
Quant Rating Neutral Buy Buy Strong Sell Buy Neutral
Trading
NCNA VRTX REGN VRNA ARGX ALNY
Last Close $3.2 $434.02 $704.31 $106.91 $929.61 $460.54
High 52 $7.03 $513.76 $788 $106.91 $929.61 $491.09
Low 52 $0.03 $366.54 $482.92 $37.86 $532.27 $224.58
Price vs. 52 Week High -54.48 % -15.52 % -10.62 % 0 % 0 % -6.22 %
Price vs. 52 Week Low 10566.7 % 18.41 % 45.84 % 182.38 % 74.65 % 105.07 %
Total Return
NCNA VRTX REGN VRNA ARGX ALNY
1 Month Return -36.88 % 4.13 % 21.84 % 0 % 10.19 % -4.39 %
3 Month Return -17.25 % 11.32 % 22.74 % 1.06 % 40.57 % 0.8 %
6 Month Return 7205.94 % -1.06 % 18.51 % 49.92 % 64.35 % 61.42 %
9 Month Return 240.46 % -6.08 % 3.57 % 66.4 % 45.48 % 84.22 %
YTD Return 168.91 % 7.78 % -1.13 % 130.21 % 51.16 % 95.72 %
1 Year Return 140.6 % -3.12 % -5.41 % 180.68 % 61.8 % 96.59 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
NCNA VRTX REGN VRNA ARGX ALNY
Dividend Yield Percentage (TTM) - - 0.47 % - - -
Dividend Paid and Capex Coverage Ration (TTM) -70.99 % 9.76 % 4.25 % -147.93 % 65.28 % 5.97 %
Dividend Per Share (TTM) - - 3.52 % - - -
Payout Ratio (TTM) - - 6.16 % - - -
Growth
NCNA VRTX REGN VRNA ARGX ALNY
Asset Growth -46.88 % 7.41 % 53.91 % 10.71 %
Gross Profit Growth - 1.16 % - 26.81 %
Revenue Growth - 0.99 % - 22.97 %
Revenue 3 Year - 20.64 % -15.89 % 147.1 %
Revenue 5 Year - 73.64 % - 775.72 %
Revenue 10 Year - 285.02 % - 2487.4 %
EBIT Growth 28.9 % 9.09 % -131.37 % 24.59 %
Net Income Growth 31.25 % 2.09 % -224.78 % 36.82 %
Net Income 3 Yeari Growth Per Share 67.12 % 6.32 % -148.34 % 69.73 %
Net Income 5 Yeari Growth Per Share 52.43 % 31.91 % 25.82 % 73.13 %
Net Income 10 Yeari Growth Per Share -160008.12 % 680.22 % -35.51 % 55.09 %
Operating Income Growth 30.43 % -7.46 % -133.02 % 37.31 %
Operating Cash Flow Growth (CFG) 27.69 % - -143.33 % -107.98 %
Operating 3 Year CFG 43.71 % -100 % -170.73 % 98.8 %
Operating 5 Year CFG 56.99 % -100 % 54.81 % 97.44 %
Operating 10 Year CFG -89.65 % -100 % 40.15 % 97.08 %
EPS Growth 37.75 % 5.31 % -214.81 % 38.07 %
EPS Diluted Growth 37.75 % 8.19 % -208.93 % 38.07 %
Book Value Per Share -64.51 % 32.88 % -22.82 % 129.75 %
Share Holder 3 Year Equity Growth Per Share -93.63 % 41.21 % 1.82 % -89.42 %
Share Holder 5 Year Equity Growth Per Share -94.97 % 191.63 % -24.45 % -96.01 %
Share Holder 10 Year Equity Growth Per Share 8877.35 % 842.11 % -71.86 % -95.83 %
Dividend Per Share Growth - - - -
Dividend 3 Year Growth Per Share - - - -
Dividend 5 Year Growth Per Share - - - -
Dividend 10 Year Growth Per Share - - - -
Debt Growth -52.02 % 0.06 % 139.05 % 110.16 %
Free Cash Flow Growth 27.89 % - -144.48 % -201.54 %
Updated On 31 Dec 2024 31 Dec 2025 31 Dec 2024 31 Dec 2024
Profitability
NCNA VRTX REGN VRNA ARGX ALNY
Gross Profit Margin TTM - 86.28 % 86.27 % 95.15 % 65.82 % 83.99 %
Return on Assets TTM -85.16 % 14.78 % 11.11 % -11.01 % 15.06 % 0.9 %
Return on Equity TTM -253.43 % 21.81 % 14.07 % -30.05 % 18.96 % 26.13 %
Return on Capital Employed TTM -62.68 % 19.59 % 9.28 % -8.31 % 5.04 % 8.03 %
Net Income Per EBT TTM 95.95 % 82.61 % 86.12 % 111.64 % 237.3 % -136.38 %
EBT Per Ebit TTM 175.72 % 111.4 % 141.65 % 130.36 % 147.38 % -12.07 %
EBIT Per Revenue TTM - 34.06 % 25.75 % -25.86 % 13.47 % 8.25 %
Cash Flow To Debt Ratio TTM -10126.47 % 202.64 % 187.41 % -29.66 % 932.29 % 9.59 %
Receivables Turnover TTM - 6.02 2.5 1.93 1.91 3.33
Payables Turnover TTM - 0.4 0.34 2.37 0.9 4.37
Inventory Turnover TTM - 0.99 0.62 0.94 2.26 6.82
Fixed Asset Turnover TTM - 388.59 % 280.11 % 6536.22 % 5009.77 % 463.12 %
Asset Turnover TTM - 47.15 % 35.36 % 29.27 % 31.97 % 66.16 %
Operating Cash Flow Per Share TTM -3.73 14.55 49.28 -0.85 5.67 2.02
Free Cash Flow Per Share TTM -3.78 13.06 40.37 -0.85 5.58 1.68
Cash Per Share TTM 682.98 % 2459.7 % 18334.11 % 511.43 % 5536.58 % 2072.79 %
Operating Cash Flow Sales Ratio TTM - 31.71 % 35.36 % -43.23 % 17.54 % 8.28 %
Free Cash Flow Operating Cash Flow Ratio TTM 101.41 % 89.76 % 81.92 % 100.75 % 98.47 % 83.26 %
Cash Flow Coverage Ratios TTM -10126.47 % 202.64 % 187.41 % -29.66 % 932.29 % 9.59 %
Price To Free Cash Flows Ratio TTM -0.67 36.72 18.43 -995.27 128.45 195.85
Price To Operating Cash Flows Ratio TTM -0.41 32.86 15.05 -126.33 145.01 162.25
Price Cash Flow Ratio TTM -0.41 32.86 15.05 -126.33 145.01 162.25
Income Statement (TTM)
NCNA VRTX REGN VRNA ARGX ALNY
Revenue $0B $11.02B $14.34B $0.03B $2.19B $2.25B
Gross Profit $0B $9.49B $12.24B $0.03B $1.96B $1.92B
Gross Profit Ratio 0% 86.11% 85.35% 93.89% 89.62% 85.62%
EBITDA $-0.02B $0.49B $5.82B $-0.12B $0.11B $-0.18B
Net Income $-0.02B $-0.54B $4.5B $-0.14B $0.83B $-0.28B
EPS Diluted -3.27 -2.08 41.48 -1.73 12.78 -2.18
Balance Sheet (MRQ)
NCNA VRTX REGN VRNA ARGX ALNY
Long Term Debt $0B $1.66B $2.71B $0.12B $0.03B $2.59B
Total Liabilities $0.01B $6.12B $9.3B $0.27B $0.7B $4.17B
Total Equity $0.01B $16.41B $31.26B $0.2B $5.5B $0.07B
Total Investments $0B $6.65B $16.08B $0.02B $1.93B $1.73B
Total Debt $0B $1.75B $2.71B $0.12B $0.04B $2.74B
Total Assets $0.01B $22.53B $40.56B $0.47B $6.2B $4.24B
Cash Flow Statement (TTM)
NCNA VRTX REGN VRNA ARGX ALNY
Net Income $-0.02B $-0.54B $4.5B $-0.17B $0.83B $-0.28B
Inventory $0B $-0.52B $-0.28B $-0.01B $-0.1B $0.01B
Dividends Paid $0B $0B $-0.37B $0B $0B $0B
Operating Cash Flow $-0.02B $-0.49B $4.98B $-0.12B $-0.08B $-0.01B
Capital Expenditure $-0B $-0.3B $-0.9B $-0B $-0.07B $-0.03B
Related Stocks
Ticker Name Price
AADI Aadi Bioscience, Inc. 2.05
AAPG 24.52
AARD Aardvark Therapeutics, Inc. Common Stock 12.65
ABCL AbCellera Biologics Inc. 3.16
ABCM Abcam plc 23.99
ABEO Abeona Therapeutics Inc. 5.13
ABIO ARCA biopharma, Inc. 28.8
ABOS Acumen Pharmaceuticals, Inc. 2.4
ABPWW 0.0155
ABSI Absci Corporation 2.695
ABUS Arbutus Biopharma Corporation 3.84
ABVC ABVC BioPharma, Inc. 1.74
ABVX Abivax SA American Depositary Shares 117.67
ACAD ACADIA Pharmaceuticals Inc. 23.56
ACER Acer Therapeutics Inc. 0.6601
ACET Adicet Bio, Inc. 7.03
ACGN Aceragen, Inc. 0.3849
ACHL Achilles Therapeutics plc 1.48
ACHV Achieve Life Sciences, Inc. 4.25
ACIU AC Immune SA 3.14
Unlock